Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus†
Article first published online: 22 APR 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 53, Issue 5, pages 1742–1751, May 2011
How to Cite
Pawlotsky, J.-M. (2011), Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology, 53: 1742–1751. doi: 10.1002/hep.24262
Potential conflict of interest: The author has received research grants from Gilead and Roche. He has served as an advisor for Abbott, Anadys, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, DebioPharm, Gilead, GlaxoSmithKline, Idenix, Janssen-Cilag, Madaus-Rottapharm, Merck, Novartis, Pfizer, Pharmasset, Roche, Schering-Plough, Tibotec, Vertex, and Virco.
- Issue published online: 22 APR 2011
- Article first published online: 22 APR 2011
- Accepted manuscript online: 3 MAR 2011 08:58AM EST
- Manuscript Accepted: 11 FEB 2011
- Manuscript Received: 24 DEC 2010
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.